You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Claims for Patent: 11,016,099

✉ Email this page to a colleague

Summary for Patent: 11,016,099

Title:	Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers
Abstract:	The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.
Inventor(s):	Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, Jr.
Assignee:	Amgen Inc, MedImmune LLC
Application Number:	US15/759,330
Patent Claims:

Details for Patent 11,016,099

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	September 25, 2009	⤷ Start Trial	2036-09-16
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	125261	December 30, 2009	⤷ Start Trial	2036-09-16
Janssen Biotech, Inc.	STELARA	ustekinumab	Injection	761044	September 23, 2016	⤷ Start Trial	2036-09-16
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	July 13, 2017	⤷ Start Trial	2036-09-16
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	January 29, 2019	⤷ Start Trial	2036-09-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.